{"page":{"totalFilteredElements":335},"studies":[{"active":true,"description":"A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer without Active Liver Metastases","eudractNumber":"2024-519929-38-00","id":11431,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06856837","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-11-19T12:35:07+01:00","shortTitle":"Quintis","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"
R-Pola-Glo – A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dosed R-CHOP
","eudractNumber":"2022-003398-51","id":8351,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD20","id":"mt_77"}],"nctNumber":"NCT05798156","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2024-01-02T14:56:14+01:00","shortTitle":"R-Pola-Glo","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTICD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)
","eudractNumber":"2022-502660-20","id":9250,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06091254","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-12-10T08:58:51+01:00","shortTitle":"R1979-HM-2298 (OLYMPIA-1)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"

An Open-Label Study to Assess the Anti-Tumor Activity and Safety of \nREGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With \nRelapsed or Refractory B-cell Non-Hodgkin Lymphom\n

","eudractNumber":"2017-002139-41","id":3873,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT03888105","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2020-08-25T14:49:57+02:00","shortTitle":"R1979-ONC-1625","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"
Radical antegrade modular pancreatosplenectomy versus conventional
distal pancreatosplenectomy for pancreatic cancer – The multicenter,
randomized controlled RAMPS-Trial
","eudractNumber":null,"id":11072,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-06-01T13:19:44+02:00","shortTitle":"RAMPS trial","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A Retrospective, Multicountry Study of Clinical Outcomes in Patients with Relapsed/ Refractory Multiple Myeloma Treated with T-cell Redirectors Outside of Clinical Trials (REALiTEC)
\n 64007957MMY4004\n [REALiTEC]
","eudractNumber":null,"id":8882,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06285318","phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-05-01T13:07:26+02:00","shortTitle":"REALiTEC","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A PHASE 2 AND PHASE 3 PERI-OPERATIVE TRIAL OF FIANLIMAB AND \nCEMIPLIMAB COMPARED WITH ANTI-PD1 ALONE IN PATIENTS WITH \nRESECTABLE STAGE III AND IV MELANOMA","eudractNumber":"2022-502825-17-00","id":9882,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"LAG-3","id":"mt_39"}],"nctNumber":"NCT06190951","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2025-10-09T09:45:47+02:00","shortTitle":"REGENERON / R3767-ONC-2208","therapeutical":true,"therapyLines":[{"id":"tl_6","name":"Adjuvant"},{"id":"tl_7","name":"Neoadjuvant"}]},{"active":true,"description":"Ropeginterferon alfa-2b bei Patienten mit Polycythemia\nvera","eudractNumber":null,"id":11329,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-15T10:54:42+02:00","shortTitle":"ROPE","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Registerplattform Hämatologische Neoplasien (RUBIN) - Erweiterung des Tumorregisters Lymphatische Neoplasien","eudractNumber":null,"id":9911,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06043011","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2023-10-23T08:42:46+02:00","shortTitle":"RUBIN","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"","eudractNumber":null,"id":11211,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":null,"shortTitle":"ReBaVeCo","therapeutical":false,"therapyLines":[]}]}